SecBot SecBot

INO

INOVIO PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001055726 Biotech & Drug Discovery
$1.40 −0.03 (−2.10%)
Nov 16 4:00 PM ET · prev $1.43
Market cap
$273.5M
Micro cap
Consensus
Buy
71% Buy or better · 7 analysts
Median target
$6.00
+329% · range $5.00–8.00
1 year
−29.3%
from $1.98 · Nov 17
30 days
+40.0%
from $1.00
52-week range
$0.6000–2.60
−46% from high · low Oct 30
Avg volume 20D
27.65M
Nov 2 spike 222.26M
Short interest
22.10M
≈20.1% of shares · +3.7%
Days to cover
1.8
at average volume
Insider net
$0
no open-market trades · since Feb 26
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 12 reports · 90 days
Balance 8 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 7/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Feb 26. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 23 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    5 of 7 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +3.7% to 22.10M shares. 1.8 days to cover, ≈20.1% of shares.

  • TrendUPTREND

    18% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 9.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCADD16,818,985$20.5M
VANGUARD CAPITAL MANAGEMENT LLCADD4,599,357$5.6M
RENAISSANCE TECHNOLOGIES LLCDOUBLED1,513,187$1.8M
Quadrature Capital LtdDOUBLED875,116$1.1M
JANE STREET GROUP, LLCDOUBLED732,944$894.2K
VANGUARD FIDUCIARY TRUST COADD622,858$759.9K
HRT FINANCIAL LPDOUBLED491,484$599.0K
UBS Group AGADD383,008$467.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 71% rate it Buy or better
Strong Buy2Buy3Hold2Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +329%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 11, 2026Piper Sandler
REITERATE
REITERATEOverweight
Nov 6, 2026Jefferies
MAINTAIN
MAINTAINBuy
Nov 2, 2026HC Wainwright & Co.
UPGRADE
UPGRADEBuy
Aug 13, 2026Jefferies
UPGRADE
UPGRADEBuy
Aug 3, 2026Piper Sandler
REITERATE
REITERATEOverweight

Washington

Corporate Lobbying

2 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
open-market buys or sells · since Feb 26
DateInsiderTypeValue
May 20, 2026
Sumner Michael John
Chief Medical Officer
May 20, 2026
TAX W/H$3.3K
May 20, 2026
Sumner Michael John
Chief Medical Officer
May 20, 2026
EXERCISE9,450 sh
May 20, 2026
Sumner Michael John
Chief Medical Officer
May 20, 2026
AWARD46,876 sh
May 20, 2026
Sumner Michael John
Chief Medical Officer
May 20, 2026
AWARD37,684 sh
May 20, 2026
Humeau Laurent
Chief Scientific Officer
May 20, 2026
EXERCISE6,027 sh
May 20, 2026
Humeau Laurent
Chief Scientific Officer
May 20, 2026
TAX W/H$2.7K
May 20, 2026
Humeau Laurent
Chief Scientific Officer
May 20, 2026
AWARD34,160 sh
May 20, 2026
Humeau Laurent
Chief Scientific Officer
May 20, 2026
AWARD27,440 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

Short side

FINRA· Oct 30, 2026
22,100,943
shares short
+3.7%
vs prior settlement
1.8
days to cover
≈20.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 11, 2026 Other
INOVIO to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Nov. 11, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a commercial-stage biotec
Nov 5, 2026 Press
Inovio priced a $75M underwritten public offering of 58.7M shares at $1.05/share plus pre-funded warrants, following…
Impact 6/10
Nov 5, 2026 Press
Inovio Pharmaceuticals announced an underwritten public offering of common stock with a 30-day underwriter option for…
Impact 4/10
Sep 30, 2026 Inst.
FMR LLC · ADD
16,818,985 shares ($20.5M)
Sep 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC · ADD
4,599,357 shares ($5.6M)
Reddit Mentions per day, 14 days
Recent posts
All social signals and their track records

SecBot reports

17 filings · 3 press releases · 1 bullish · 12 bearish · 4 neutral
All INO filing & press-release reports (20)